Quick Answer
Q32 Bio Inc. reported Diluted EPS of $2.42 per share for fiscal year 2025.
Q32 Bio Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.42 | +136.8% |
| 2024 | -$6.58 | +95.7% |
| 2023 | -$153.96 | -170966.7% |
| 2022 | -$0.09 | +94.8% |
| 2021 | -$1.73 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.60 | +58.9% | +23.1% |
| June 30, 2025 | -$0.78 | +45.1% | +13.3% |
| March 31, 2025 | -$0.90 | +85.8% | +38.4% |
| September 30, 2024 | -$1.46 | +96.4% | -2.8% |
| June 30, 2024 | -$1.42 | +91.5% | +77.6% |
| March 31, 2024 | -$6.33 | +68.1% | +84.4% |
| September 30, 2023 | -$40.52 | -6767.8% | -142.8% |
| June 30, 2023 | -$16.69 | -3172.5% | +15.9% |
- Q32 Bio Inc. showed an increase of +136.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Q32 Bio Inc.’s diluted eps has grown by 239.9% (from $1.73 per share (loss) to $2.42 per share).
- The most recent figure is from Q32 Bio Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: